Share
Export Citation
APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review
Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial
Nurdin A.
Vaccine
Q1Published: 2024Citations: 11
Abstract
IndoVac in adults showed favourable safety profile and elicited non-inferior immune response to Covovax. (ClinicalTrials.gov: NCT05433285, Indonesian Clinical Research Registry: INA-R5752S9).
Access to Document
10.1016/j.vaccine.2024.03.077Other files and links
- Link to publication in Scopus
- Open Access Version Available
Fingerprint
ImmunogenicitySciences
MedicineSciences
VirologySciences
AlumSciences
AdjuvantSciences
Recombinant DNASciences
ImmunologySciences
AntibodySciences
BiologySciences
ChemistrySciences
Organic chemistrySciences
BiochemistrySciences
GeneSciences